糖尿病药物的事先授权:临床结果和健康差异
Ella Salter1, Aimee Louks2, Catherine Pham3
1Ambulatory Care Department, Franciscan Health, Indianapolis, IN, USA.
Diabetes & metabolic syndrome
|February 4, 2024
概括
糖尿病药物的预先授权改善了A1c水平,但观察到差异. 接受原始或替代药物治疗的患者比不接受原始或替代药物治疗的患者表现更好. 在事先授权过程中存在健康差异.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 药物经济学 药物经济学
- 临床结果 临床结果
背景情况:
- 预先授权 (PA) 是医疗计划的成本控制策略.
- 肺炎可能导致治疗延迟,放弃治疗,并加剧健康差异.
- 这项研究调查了糖尿病 (DM) 药物的PA.
研究的目的:
- 评估DM药物的PA临床结果.
- 为了确定与DM药物的PA过程相关的健康差异.
主要方法:
- 美国成人患者的观察队列研究,需要用于DM药物的PA.
- 患者被分为:PA Med,替代的DM Med或没有Med.
- 主要结局:血红蛋白A1c (HbA1c) 的变化;使用多变量逻辑回归.
主要成果:
- 包括6305名患者;PA Med (2434) 和DM Med (1323) 组显示HbA1c降低比No Med (2548) 更多.
- PA Med: -0.9% HbA1c 变化; DM Med: -1.0% HbA1c 变化; 没有 Med: -0.4% HbA1c 变化 (p < 0.05).
- 西班牙裔/拉丁裔患者,那些没有整合的处方医生和更高的慢性疾病负担与No Med组有关.
结论:
- 接受DM药物后的PA与改善的临床结果有关.
- 在糖尿病药物的事先授权过程中存在健康差异.
相关概念视频
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Symptoms, Diagnosis, and Complications
544
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
544
Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174


